GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Swedish Orphan Biovitrum AB (OTCPK:SWOBY) » Definitions » E10

Swedish Orphan Biovitrum AB (Swedish Orphan Biovitrum AB) E10 : $0.36 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Swedish Orphan Biovitrum AB E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Swedish Orphan Biovitrum AB's adjusted earnings per share data for the three months ended in Mar. 2024 was $0.112. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $0.36 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Swedish Orphan Biovitrum AB's average E10 Growth Rate was 15.70% per year. During the past 3 years, the average E10 Growth Rate was 25.50% per year. During the past 5 years, the average E10 Growth Rate was 37.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Swedish Orphan Biovitrum AB was 117.50% per year. The lowest was 25.50% per year. And the median was 41.60% per year.

As of today (2024-05-24), Swedish Orphan Biovitrum AB's current stock price is $13.59. Swedish Orphan Biovitrum AB's E10 for the quarter that ended in Mar. 2024 was $0.36. Swedish Orphan Biovitrum AB's Shiller PE Ratio of today is 37.75.

During the past 13 years, the highest Shiller PE Ratio of Swedish Orphan Biovitrum AB was 544.45. The lowest was 28.96. And the median was 51.48.


Swedish Orphan Biovitrum AB E10 Historical Data

The historical data trend for Swedish Orphan Biovitrum AB's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Swedish Orphan Biovitrum AB E10 Chart

Swedish Orphan Biovitrum AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 0.35

Swedish Orphan Biovitrum AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.35 0.36

Competitive Comparison of Swedish Orphan Biovitrum AB's E10

For the Drug Manufacturers - Specialty & Generic subindustry, Swedish Orphan Biovitrum AB's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Swedish Orphan Biovitrum AB's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Swedish Orphan Biovitrum AB's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Swedish Orphan Biovitrum AB's Shiller PE Ratio falls into.



Swedish Orphan Biovitrum AB E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Swedish Orphan Biovitrum AB's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.112/132.2054*132.2054
=0.112

Current CPI (Mar. 2024) = 132.2054.

Swedish Orphan Biovitrum AB Quarterly Data

per share eps CPI Adj_EPS
201406 0.007 100.432 0.009
201409 0.013 100.161 0.017
201412 -0.004 100.225 -0.005
201503 0.016 99.950 0.021
201506 -0.001 99.995 -0.001
201509 0.001 100.228 0.001
201512 -0.003 100.276 -0.004
201603 0.064 100.751 0.084
201606 0.066 101.019 0.086
201609 0.028 101.138 0.037
201612 0.015 102.022 0.019
201703 0.040 102.022 0.052
201706 0.054 102.752 0.069
201709 0.072 103.279 0.092
201712 0.075 103.793 0.096
201803 0.110 103.962 0.140
201806 0.137 104.875 0.173
201809 0.123 105.679 0.154
201812 0.116 105.912 0.145
201903 0.160 105.886 0.200
201906 0.086 106.742 0.107
201909 0.090 107.214 0.111
201912 0.233 107.766 0.286
202003 0.193 106.563 0.239
202006 0.049 107.498 0.060
202009 0.050 107.635 0.061
202012 0.287 108.296 0.350
202103 0.130 108.360 0.159
202106 0.051 108.928 0.062
202109 0.088 110.338 0.105
202112 0.220 112.486 0.259
202203 0.091 114.825 0.105
202206 0.041 118.384 0.046
202209 0.065 122.296 0.070
202212 0.214 126.365 0.224
202303 0.162 127.042 0.169
202306 0.033 129.407 0.034
202309 0.014 130.224 0.014
202312 0.146 131.912 0.146
202403 0.112 132.205 0.112

Add all the adjusted EPS together and divide 10 will get our e10.


Swedish Orphan Biovitrum AB  (OTCPK:SWOBY) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Swedish Orphan Biovitrum AB's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=13.59/0.36
=37.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Swedish Orphan Biovitrum AB was 544.45. The lowest was 28.96. And the median was 51.48.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Swedish Orphan Biovitrum AB E10 Related Terms

Thank you for viewing the detailed overview of Swedish Orphan Biovitrum AB's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Swedish Orphan Biovitrum AB (Swedish Orphan Biovitrum AB) Business Description

Traded in Other Exchanges
Address
Tomtebodavagen 23 A, Solna, Stockholm, SWE, SE-112 76
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016. Sobi has since been building its immunology pipeline (rare disease drug Gamifant, U.S. rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and hematology pipeline outside of hemophilia (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).